SHAREHOLDER ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Dynavax Technologies Corp. & Encourage...
November 23 2016 - 10:49AM
Business Wire
Goldberg Law PC, a national shareholder rights litigation firm,
announces the filing of a class action lawsuit against Dynavax
Technologies Corporation (“Dynavax” or the “Company”) (Nasdaq:
DVAX). Investors who purchased or otherwise acquired shares between
March 10, 2014 and November 11, 2016 inclusive (the “Class
Period”), are encouraged to contact the firm in advance of the
January 17, 2017 lead plaintiff motion
deadline.
If you are a shareholder who suffered a loss during the Class
Period, click here to participate. In addition, we encourage
you to contact Michael Goldberg or Brian Schall, of Goldberg Law
PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at
800-977-7401, to discuss your rights free of charge. You can also
reach us through the firm’s website at
http://www.Goldberglawpc.com, or by email at
info@goldberglawpc.com.
The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
The complaint alleges that during the Class Period, Dynavax made
false and/or misleading statements and/or failed to disclose: that
the phase 3 HBV-23 trial for the Company’s lead vaccine product
HEPLISAV-B was not designed in accordance with the U.S. Food and
Drug Administration’s concerns and issues; that the Company failed
to provide sufficient information to the FDA in its Revised
Biologics License Application for the drug; that Dynavax’s
resources will not be sufficient for the Company to advance the
HEPLISAV-B program on its own; and that as a result of the above,
the Company’s financial statements and statements about its
business, operations, and prospects were false and misleading
and/or lacked a reasonable basis. On November 14, 2016, Dynavax
announced that it received a Complete Response Letter from the U.S.
Food and Drug Administration requesting additional information on
the Company’s HEPLISAV-B product in connection with its Biologics
License Application. When this news was announced to the public,
shares of Dynavax fell in value, causing investors harm.
Goldberg Law PC represents shareholders around the world and
specializes in securities class actions and shareholder rights
litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161123005539/en/
Goldberg Law PC, Los AngelesMichael Goldberg, Esq.,
800-977-7401Brian Schall, Esq.,
800-977-7401info@goldberglawpc.comwww.Goldberglawpc.com
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From May 2023 to May 2024